Swedish Orphan Biovitrum AB (publ)
Swedish Orphan Biovitrum AB (publ) Fundamental Analysis
Swedish Orphan Biovitrum AB (publ) (BIOVF) shows weak financial fundamentals with a PE ratio of 234.40, profit margin of 1.75%, and ROE of 1.30%. The company generates $28.2B in annual revenue with strong year-over-year growth of 17.65%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 56.7/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze BIOVF's fundamental strength across five key dimensions:
Efficiency Score
WeakBIOVF struggles to generate sufficient returns from assets.
Valuation Score
ModerateBIOVF shows balanced valuation metrics.
Growth Score
ExcellentBIOVF delivers strong and consistent growth momentum.
Financial Health Score
ModerateBIOVF shows balanced financial health with some risks.
Profitability Score
ModerateBIOVF maintains healthy but balanced margins.
Key Financial Metrics
Is BIOVF Expensive or Cheap?
P/E Ratio
BIOVF trades at 234.40 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, BIOVF's PEG of 0.03 indicates potential undervaluation.
Price to Book
The market values Swedish Orphan Biovitrum AB (publ) at 3.07 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 9.59 times EBITDA. This is generally considered low.
How Well Does BIOVF Make Money?
Net Profit Margin
For every $100 in sales, Swedish Orphan Biovitrum AB (publ) keeps $1.75 as profit after all expenses.
Operating Margin
Core operations generate 26.77 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $1.30 in profit for every $100 of shareholder equity.
ROA
Swedish Orphan Biovitrum AB (publ) generates $0.73 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Swedish Orphan Biovitrum AB (publ) generates strong operating cash flow of $8.55B, reflecting robust business health.
Free Cash Flow
Swedish Orphan Biovitrum AB (publ) generates strong free cash flow of $8.11B, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $23.45 in free cash annually.
FCF Yield
BIOVF converts 7.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
234.40
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.03
vs 25 benchmark
P/B Ratio
Price to book value ratio
3.07
vs 25 benchmark
P/S Ratio
Price to sales ratio
4.11
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.31
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.90
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.01
vs 25 benchmark
ROA
Return on assets percentage
0.007
vs 25 benchmark
ROCE
Return on capital employed
0.15
vs 25 benchmark
How BIOVF Stacks Against Its Sector Peers
| Metric | BIOVF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 234.40 | 29.78 | Worse (Expensive) |
| ROE | 1.30% | 792.00% | Weak |
| Net Margin | 1.75% | -23280.00% (disorted) | Weak |
| Debt/Equity | 0.31 | 0.25 | Weak (High Leverage) |
| Current Ratio | 0.90 | 4.60 | Weak Liquidity |
| ROA | 0.73% | -18077.00% (disorted) | Weak |
BIOVF outperforms its industry in 0 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Swedish Orphan Biovitrum AB (publ)'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
63.78%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
5.42%
Industry Style: Defensive, Growth, Innovation
GrowingFCF CAGR
82.28%
Industry Style: Defensive, Growth, Innovation
High Growth